Comparing the current results to its competitors, Immunoprecise Antibodies Ltd reported Revenue increase in the 4 quarter 2024 by 18.65 % year on year. The sales growth was above Immunoprecise Antibodies Ltd 's competitors' average revenue growth of 3.81 %, achieved in the same quarter.
Immunoprecise Antibodies Ltd , slower than the average decrease reported by the company's competitors of -69.46 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -69.46 %
Immunoprecise Antibodies Ltd 's Comment on Competition and Industry Peers
The Company operates in the AI-driven drug discovery and biologics platform sector, competing alongside full-service contract research organizations (CROs) and in-house research and development departments of biopharmaceutical firms. Its CRO and biologics services competitors include Abveris Inc., Genovac GmbH (formerly part of Aldevron LLC), Antibody Solutions, Genscript Biotech Corp, Lake Pharma Inc. (now part of Curia Inc.), as well as various specialty and regional CROs. Key competitive factors in the industry encompass therapeutic area experience, staff and service quality, reliability, service range, recruitment capabilities for principal investigators and patients, management of large-scale global clinical trials, global presence, speed of project completion, pricing, and overall value. The Company cites its full-service model, therapeutic expertise, global platform, and experienced management team as competitive strengths. Nonetheless, some competitors possess greater financial resources, broader service offerings, wider geographic reach, and niche specializations such as antibody development targeting glycosylated peptides or specific chemical modifications, which may present competitive challenges.
Overall company sales advanced by 18.65 % Immunoprecise Antibodies Ltd outperformed its competitors in this segment and improved market share, to approx. 0.07 %. << More on IPA Market Share.
*Market share is calculated based on total revenue.
April 11, 2025
In the rapidly evolving landscape of biotherapeutics, ImmunoPrecise Antibodies Ltd. (IPA) is making significant strides in alignment with the U.S. Food and Drug Administration s (FDA) recent push to phase out animal testing methods. The company s proprietary AI-driven platform, LENSai, has placed it at the forefront of this transition, reflecting a growing industry trend towards more ethical and efficient testing methodologies.ImmunoPrecise s endorsement of the FDA s initiative marks a pivotal moment for the company, underscoring its commitment to advancing biotherapeutic technologies in harmony with modern regulatory standards. The integration of LENSai enables the prediction of therapeutic responses with h...
December 3, 2024
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA), a Canada-based AI-driven biotherapeutic research and technology company, has announced its plans to release its financial results for the second quarter of the fiscal year 2025 on December 10, 2024. The announcement includes a conference call set for 10:30 am Eastern Time, during which management will discuss the financial performance and recent business highlights. This follows a press release that will detail the financial results prior to the call.As the company prepares for this pivotal update, it faces a critical backdrop: over the course of the month, ImmunoPrecise Antibodies’ shares have trailed the overall market performance, raising concerns among invest...
November 13, 2024
Victoria, British Columbia Immunoprecise Antibodies Ltd. (NASDAQ: IPA), a trailblazer in AI-driven medical innovation, has announced a major breakthrough in its cancer research initiatives, positioning itself as a key player in the burgeoning antibody market set to surpass $20.7 billion by 2030. The company s commitment to pioneering high-impact antibody development marks a significant milestone in its mission to combat cancer through innovative therapeutic approaches. Utilizing advanced artificial intelligence technologies, IPA has successfully enhanced the design and efficacy of next-generation antibody-drug conjugates (ADCs), which are critical in improving treatment options for cancer patients.Incorpo...
November 4, 2024
Unveiling the Future of AI and Biologics: ImmunoPrecise Antibodies Ltd. s Groundbreaking Innovations and DevelopmentsImmunoPrecise Antibodies Ltd. (IPA), a leading AI-driven biotherapeutic research and technology company, is poised to redefine the boundaries of biologics innovation through a series of strategic advancements. With headquarters in Victoria, British Columbia, IPA is making significant strides in the biotechnology landscape, driven by its commitment to integrate artificial intelligence (AI) into antibody engineering and development. This article provides an overview of IPA s recent announcements, highlighting their latest technological achievements and financial performance. TECHDAY Event: Show...
August 26, 2024
ImmunoPrecise Antibodies: An Overview of the Notification and Its Implications In a significant development for ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), the biotherapeutics company received notification from the Nasdaq Global Market on August 19, 2024, highlighting a failure to meet the minimum bid price requirement outlined in Nasdaq Rule 5450(a)(1). This notification, which signals a pivotal moment for the Victoria, British Columbia-based firm, raises questions about the company’s compliance strategy and future market position amid challenges in the biopharmaceutical landscape. Understanding the Nasdaq Rule 5450(a)(1) The Nasdaq Rule 5450(a)(1) mandates that companies maintain a minimum bid price of ...
August 24, 2024
In the grand parlance of commerce, wherein the fabric of ambition is often interwoven with the tendrils of adversity, we find ourselves drawn to the tale of ImmunoPrecise Antibodies Ltd. an esteemed entity hailing from the picturesque vistas of Victoria, British Columbia. On the nineteenth day of August in the year twenty twenty-four, this AI-driven biotherapeutics company received a most disconcerting missive from the revered custodians of the Nasdaq Global Market commonly known as Nasdaq. This missive, henceforth referred to as the Notification Letter, bore tidings that would strike the hearts of investors with pangs of concern.It is disclosed therein that ImmunoPrecise, emblematic of cutting-edge innovati...
July 24, 2024
Victoria, British Columbia - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company) has announced significant developments in both its financial reporting schedule and product offerings. Below, we outline the key updates pertaining to these latest announcements. Financial Results RescheduledImmunoPrecise Antibodies Ltd. has rescheduled the release of its financial results for the full fiscal year 2024. Initially slated for July 25, 2024, the release has been moved to Monday, July 29, 2024. An earnings call will be held the same day at 10:30 AM Eastern Time to discuss these results and recent business highlights.The rescheduling was deemed necessary to provide the Company s auditors with additional...
June 25, 2024
IPAs Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai VICTORIA, British Columbia - ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), a leading AI-driven biotherapeutic research and technology company, is proud to announce a significant collaboration between its subsidiary, BioStrand, and PGxAI. This strategic partnership aims to revolutionize the precision medicine field of pharmacogenomics by harnessing the power of BioStrand s groundbreaking technology - the patented Foundation AI Model, LENSai.Pharmacogenomics is an emerging field that studies how individual genetic variations can impact an individual s re...
June 10, 2024
BioStrand, a subsidiary of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), has recently launched a groundbreaking software called LENSai API for AI-driven drug discovery. This advanced software solution, based on artificial intelligence, is now commercially available. BioStrand made the announcement and provided further details during a live presentation at 2:00 pm ET.LENSai API is designed to revolutionize the drug discovery process by leveraging the power of AI technology. The software offers a customizable interface, allowing users to tailor it to their specific needs. By harnessing AI algorithms, LENSai API can analyze vast amounts of biological data and provide valuable insights to expedite the development...
October 23, 2023
IPA Expands Growth Strategy Amid Recent Market Developments VICTORIA, British Columbia - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is providing an update on its overall growth strategy in response to recent market developments. With a steadfast commitment to expanding its contract research organization (CRO) capabilities and leveraging technology to drive innovation and efficiency, IPA aims to maintain its position as a leader in the field. One of the key drivers of IPA s growth strategy is the pioneering work being conducted at its subsidiary, BioStrand. This subsidiary serves as a robust platform for the advancement of biotherapeutic r...
Publicly Traded Peers of Immunoprecise Antibodies Ltd
Cryoport inc Share Performance
-3.84%
Over The Past 5 Days
Cryoport inc
Profile
Cryoport Inc's business model revolves around providing temperature-controlled logistics solutions for the shipping of cryogenic products, including life sciences materials, cell and gene therapies, and reproductive medicine. The company utilizes its advanced technology and a global network of partners to ensure safe and secure transportation of these sensitive materials, catering to the needs of the rapidly growing biopharmaceutical industry.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Sources:
Immunoprecise Antibodies Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immunoprecise Antibodies Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
